Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IVAN SUNER

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1164522793
CMS profile
97811
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$55,616.11

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IVAN SUNER

NPI 1164522793 · CMS profile ID 97811

Allopathic & Osteopathic Physicians / Ophthalmology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164522793?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IVAN SUNER, NPI 1164522793, CMS profile ID 97811. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164522793?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). IVAN SUNER, NPI 1164522793, CMS profile ID 97811. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164522793?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
IVAN SUNER, NPI 1164522793, CMS profile ID 97811, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1164522793?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $55,616.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ocular Therapeutix, Inc. $191.0205/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148199111 CMS
Ocular Therapeutix, Inc. $18.0505/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148199119 CMS
Regeneron Healthcare Solutions, Inc. $22.9005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114204326 CMS
Genentech USA, Inc. $23.8605/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023023 CMS
Sandoz Inc. $26.2704/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089368538 CMS
Alimera Sciences, Inc. $130.0004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092825819 CMS
Astellas Pharma US Inc $28.4404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139332484 CMS
Apellis Pharmaceuticals, Inc. $26.2504/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021975 CMS
Genentech USA, Inc. $121.9704/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023027 CMS
Regeneron Pharmaceuticals, Inc. $112.6404/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114405585 CMS
Alimera Sciences, Inc. $5.6004/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092832779 CMS
Regeneron Healthcare Solutions, Inc. $28.9604/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114204319 CMS
Apellis Pharmaceuticals, Inc. $4,257.0003/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021941 CMS
Genentech USA, Inc. $21.5603/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023043 CMS
Apellis Pharmaceuticals, Inc. $33.8403/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021985 CMS
Apellis Pharmaceuticals, Inc. $294.0003/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021995 CMS
Apellis Pharmaceuticals, Inc. $29.2303/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022001 CMS
Bausch & Lomb Americas Inc. $124.9903/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140355430 CMS
Apellis Pharmaceuticals, Inc. $8,041.0003/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154022003 CMS
Sandoz Inc. $29.0603/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089368506 CMS
Apellis Pharmaceuticals, Inc. $9,933.0003/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021999 CMS
Apellis Pharmaceuticals, Inc. $119.6803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021989 CMS
Apellis Pharmaceuticals, Inc. $718.1803/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021991 CMS
Apellis Pharmaceuticals, Inc. $206.2403/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021997 CMS
Ocular Therapeutix, Inc. $1.3403/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148199107 CMS
Ocular Therapeutix, Inc. $20.5203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148199109 CMS
Apellis Pharmaceuticals, Inc. $108.6202/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021971 CMS
Astellas Pharma US Inc $3,055.0002/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139439166 CMS
Bausch & Lomb Americas Inc. $17.3802/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140355434 CMS
Apellis Pharmaceuticals, Inc. $345.6002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021981 CMS
Apellis Pharmaceuticals, Inc. $930.6402/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021983 CMS
Apellis Pharmaceuticals, Inc. $93.2202/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021987 CMS
Regeneron Pharmaceuticals, Inc. $49.4302/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114405583 CMS
Genentech USA, Inc. $133.9502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023019 CMS
Ocular Therapeutix, Inc. $23.4201/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148199113 CMS
ABBVIE INC. $125.0001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106184001 CMS
Coherus Biosciences Inc. $26.4401/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278002 CMS
Apellis Pharmaceuticals, Inc. $1,500.0001/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021993 CMS
Apellis Pharmaceuticals, Inc. $30.1401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021961 CMS
Genentech USA, Inc. $135.9501/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023014 CMS
Genentech USA, Inc. $25.8401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133023051 CMS
Regeneron Pharmaceuticals, Inc. $32.8701/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114405581 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $55,641.64 88
PY2020 $37,796.32 37
PY2021 $31,755.08 56
PY2022 $91,264.11 102
PY2023 $71,674.08 93
PY2024 $55,616.11 92
PY2025 $34,203.66 58

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,092.63 2
PY2025 Principal investigator $160,688.88 44
PY2024 Recipient $32,258.90 17
PY2024 Principal investigator $236,322.52 56
PY2023 Principal investigator $350,238.21 105
PY2022 Recipient $3,515.20 1
PY2022 Principal investigator $540,158.07 98
PY2021 Principal investigator $739,967.66 71
PY2020 Recipient $1,942.00 1
PY2020 Principal investigator $867,258.49 84
PY2019 Recipient $2,969.89 1
PY2019 Principal investigator $445,495.41 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $686.34 12/15/2025 Non-covered Recipient Entity
Retina Associates of Florida
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236558
Principal investigator 1 Genentech, Inc. $9,168.00 12/08/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644037
Principal investigator 1 Genentech, Inc. $11.97 11/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644029
Principal investigator 1 Genentech, Inc. $767.36 11/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644033
Principal investigator 1 Genentech, Inc. $385.15 11/03/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644026
Principal investigator 1 Genentech, Inc. $130.70 10/29/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644022
Principal investigator 1 Genentech, Inc. $6,258.00 10/17/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643972
Principal investigator 1 Ocular Therapeutix, Inc. $1,690.39 10/15/2025 Non-covered Recipient Entity
Retina Associates of Florida
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236554
Principal investigator 1 Genentech, Inc. $148.89 10/14/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644018
Principal investigator 1 Genentech, Inc. $69.90 10/06/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644015
Principal investigator 1 Genentech, Inc. $1,705.23 09/29/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643969
Principal investigator 1 Genentech, Inc. $8,567.00 09/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643961
Principal investigator 1 Apellis Pharmaceuticals, Inc. $250.00 09/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363616
Recipient F. Hoffmann-La Roche AG $561.67 09/09/2025 Covered Recipient Physician Association of early macular leakage resolution with extended treatment intervals in patients with RVO: A BALATON/COMINO post hoc analysis No dispute reported 06/30/2026 1211536159
Principal investigator 1 Genentech, Inc. $176.00 08/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643966
Principal investigator 1 Genentech, Inc. $1,640.00 07/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644009
Principal investigator 1 Genentech, Inc. $1,886.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644001
Principal investigator 1 Genentech, Inc. $23.84 07/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644003
Principal investigator 1 Genentech, Inc. $740.97 07/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211644007
Principal investigator 1 Genentech, Inc. $15,744.00 07/07/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643957
Recipient Ocular Therapeutix, Inc. $10,530.96 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229280
Principal investigator 1 Genentech, Inc. $723.00 06/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643881
Principal investigator 1 Genentech, Inc. $7,263.00 06/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643896
Principal investigator 1 Genentech, Inc. $20,492.00 06/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643900
Principal investigator 1 Genentech, Inc. $176.00 06/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643904
Principal investigator 1 Genentech, Inc. $852.29 06/17/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643978
Principal investigator 1 Genentech, Inc. $10.96 06/17/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643983
Principal investigator 1 Genentech, Inc. $242.00 06/11/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643892
Principal investigator 1 Genentech, Inc. $168.00 06/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643885
Principal investigator 1 Genentech, Inc. $5,536.00 06/02/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643974
Principal investigator 1 ANI Pharmaceuticals, Inc. $11,014.17 05/15/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA LLC
New Day Study No dispute reported 06/30/2026 1248567431
Principal investigator 1 Genentech, Inc. $43.68 05/02/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643996
Principal investigator 1 Genentech, Inc. $54.04 04/22/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643993
Principal investigator 1 Genentech, Inc. $1,563.00 04/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643928
Principal investigator 1 Genentech, Inc. $318.00 04/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643936
Principal investigator 1 Genentech, Inc. $504.00 04/16/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643942
Principal investigator 1 Genentech, Inc. $25,989.00 04/11/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643945
Principal investigator 1 Genentech, Inc. $18,958.00 03/26/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643931
Principal investigator 1 Genentech, Inc. $723.00 03/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643923
Principal investigator 1 Genentech, Inc. $734.00 03/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643950
Principal investigator 1 Genentech, Inc. $568.00 03/19/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211643954
Principal investigator 1 Genentech, Inc. $855.00 02/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643907
Principal investigator 1 Genentech, Inc. $3,795.00 02/18/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211643989
Principal investigator 1 Genentech, Inc. $4,938.00 02/04/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643912
Principal investigator 1 Genentech, Inc. $3,651.00 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211643916
Principal investigator 1 Genentech, Inc. $1,468.00 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF FLORIDA PA
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211643920